Karen Perls, PA
Physician Assistant · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Karen Perls’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A50154 · Current
Licensed to practise in California · since 1991 · expires 2027-05-31 · University of Liverpool Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Mountain View Endoscopy Center, LPAmbulatory Surgery Center · Mountain View, CAOwner · accredited by JCInitial Accreditation1 inspection, 1 with deficiencies · last 2013-06-03: Requirements Met
Original Medicare doctor bills
$12,513
Medicare paid this office $12,513 for 111 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 31 | $4,859 | $135 |
| Return visit (30+ min) | 29 | $2,791 | $93 |
| New patient visit (45+ min) | 17 | $2,029 | $119 |
| New patient visit (30+ min) | 14 | $1,123 | $80 |
| Short return visit (20+ min) | 14 | $990 | $71 |
See all 6 services
| Long return visit (40+ min) | 31 | $4,859 | $135 |
| Return visit (30+ min) | 29 | $2,791 | $93 |
| New patient visit (45+ min) | 17 | $2,029 | $119 |
| New patient visit (30+ min) | 14 | $1,123 | $80 |
| Short return visit (20+ min) | 14 | $990 | $71 |
| Measurement of liver stiffness | 11 | $200 | $18 |
Who their Medicare patients are
111 Original Medicare patients in 2024. Average age 78 · Women 62% · Health risk score 1.05. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 67% · Diabetes 25% · Coronary heart disease 23% · Chronic kidney disease 20% · Atrial fibrillation 20% · Cancer 14% · Depression 14% · Heart failure 12%.
The office billed $52,427, Medicare allowed $17,519 and paid $12,513; for 134 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 111 | 134 | 78 | 1.05 | $52,427 | $12,513 |
| 2023 | 116 | 162 | 76 | 1.21 | $66,674 | $16,686 |
| 2022 | 162 | 202 | 77 | 1.24 | $74,123 | $19,299 |
| 2021 | 166 | 212 | 76 | 1.16 | $71,151 | $20,789 |
| 2020 | 68 | 91 | 76 | 1.42 | $29,943 | $7,332 |
| 2019 | 120 | 166 | 77 | 1.04 | $60,103 | $14,602 |
| 2018 | 126 | 164 | 76 | 1.30 | $55,809 | $14,069 |
| 2017 | 90 | 112 | 76 | 1.25 | $37,826 | $9,454 |
| 2016 | 67 | 88 | 76 | 1.19 | $24,308 | $6,625 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 55 | $8,254 | $135 |
| Return visit (30+ min) | 39 | $4,086 | $87 |
| New patient visit (45+ min) | 17 | $2,134 | $126 |
2022: 6 services
| Long return visit (40+ min) | 36 | $5,825 | $142 |
| Return visit (30+ min) | 49 | $5,537 | $99 |
| New patient visit (45+ min) | 20 | $2,452 | $123 |
| New patient visit (30+ min) | 32 | $2,431 | $76 |
| Short return visit (20+ min) | 21 | $1,315 | $63 |
| Measurement of liver stiffness | 12 | $333 | $28 |
2021: 5 services
| Return visit (30+ min) | 85 | $10,515 | $104 |
| Long return visit (40+ min) | 26 | $3,902 | $150 |
| Short return visit (20+ min) | 28 | $1,953 | $70 |
| New patient visit (45+ min) | 15 | $1,900 | $127 |
| Measurement of liver stiffness | 18 | $527 | $29 |
2020: 2 services
| Return visit (30+ min) | 48 | $4,878 | $79 |
| New patient visit (45+ min) | 11 | $1,238 | $113 |
2019: 4 services
| Return visit (30+ min) | 73 | $7,749 | $80 |
| New patient visit (45+ min) | 34 | $4,224 | $124 |
| Long return visit (40+ min) | 12 | $1,420 | $118 |
| Short return visit (20+ min) | 14 | $856 | $54 |
2018: 3 services
| Return visit (30+ min) | 75 | $8,037 | $83 |
| New patient visit (45+ min) | 33 | $4,086 | $124 |
| Short return visit (20+ min) | 15 | $885 | $59 |
2017: 3 services
| Return visit (30+ min) | 51 | $5,519 | $84 |
| New patient visit (45+ min) | 21 | $2,651 | $126 |
| New patient visit (30+ min) | 11 | $577 | $52 |
2016: 3 services
| Short return visit (20+ min) | 35 | $2,819 | $59 |
| New patient visit (30+ min) | 16 | $1,371 | $86 |
| Return visit (30+ min) | 13 | $1,205 | $86 |
Drugs they prescribed that Part D paid
$15,707
Pharmacies billed $15,707 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 275) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
257 generic and 18 brand-name prescriptions · $15,707 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pantoprazole | 70 | $1,100 | $16 |
| Famotidine | 69 | $1,059 | $15 |
| Omeprazole | 36 | $624 | $17 |
| Esomeprazole Magnesium | 13 | $482 | $37 |
| Peg 3350-Electrolyte | 19 | $360 | $19 |
Year by year
| 2024 | 275 | 105 | 0% (0) | 7% | $15,707 |
| 2023 | 288 | 103 | 0% (0) | 14% | $56,826 |
| 2022 | 316 | 135 | 0% (0) | 16% | $21,009 |
| 2021 | 275 | 132 | 0% (0) | 28% | $30,862 |
| 2020 | 175 | 90 | 0% (0) | 36% | $71,974 |
| 2019 | 187 | 109 | 0% (0) | 41% | $157,819 |
| 2018 | 146 | 94 | 0% (0) | 47% | $11,742 |
| 2017 | 150 | 79 | 0% (0) | 37% | $14,741 |
| 2016 | 75 | 40 | 0% (0) | 27% | $5,160 |
| 2015 | 17 | None | 0% (0) | None | $1,113 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Famotidine | 62 | $1,445 | $23 |
| Pantoprazole | 68 | $1,180 | $17 |
| Omeprazole | 48 | $1,005 | $21 |
| Esomeprazole Magnesium | 12 | $847 | $71 |
| Peg 3350-Electrolyte | 24 | $517 | $22 |
2022: 5 drugs
| Suprep | 20 | $2,312 | $116 |
| Pantoprazole | 64 | $1,214 | $19 |
| Famotidine | 69 | $1,176 | $17 |
| Peg 3350-Electrolyte | 34 | $658 | $19 |
| Omeprazole | 49 | $634 | $13 |
2021: 7 drugs
| Dexilant | 11 | $8,856 | $805 |
| Linzess | 12 | $5,759 | $480 |
| Suprep | 35 | $3,908 | $112 |
| Famotidine | 56 | $1,104 | $20 |
| Pantoprazole | 42 | $823 | $20 |
| Omeprazole | 29 | $443 | $15 |
| Peg 3350-Electrolyte | 20 | $381 | $19 |
2020: 6 drugs
| Suprep | 26 | $2,710 | $104 |
| Pantoprazole | 28 | $514 | $18 |
| Famotidine | 23 | $361 | $16 |
| Peg 3350-Electrolyte | 16 | $238 | $15 |
| Omeprazole | 20 | $208 | $10 |
| Gavilyte-N | 11 | $168 | $15 |
2019: 6 drugs
| Suprep | 35 | $3,483 | $100 |
| Peg 3350-Electrolyte | 23 | $416 | $18 |
| Pantoprazole | 19 | $364 | $19 |
| Omeprazole | 29 | $255 | $9 |
| Dicyclomine | 11 | $133 | $12 |
| Ranitidine | 21 | $130 | $6 |
2018: 4 drugs
| Suprep | 46 | $4,354 | $95 |
| Pantoprazole | 28 | $251 | $9 |
| Gavilyte-N | 11 | $177 | $16 |
| Ranitidine | 13 | $115 | $9 |
2017: 5 drugs
| Suprep | 23 | $2,034 | $88 |
| Moviprep | 22 | $2,029 | $92 |
| Pantoprazole | 39 | $405 | $10 |
| Omeprazole | 17 | $193 | $11 |
| Ranitidine | 15 | $187 | $12 |
2016: 1 drug
| Pantoprazole | 26 | $294 | $11 |
Money from drug and device companies
$393 in 2025
| 2025 | 2 | 4 | None | $393 |
| 2024 | 1 | 1 | None | $44 |
| 2022 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $270 | 3 payments
|
| Genzyme | Dupixent | $123 | 1 payment
|
See all 4 published payments
| Janssen Biotech | Meals · 2025-10-29 | Tremfya | $37 |
| Janssen Biotech | Meals · 2025-09-19 | Tremfya | $114 |
| Genzyme | Meals · 2025-08-20 | Dupixent | $123 |
| Janssen Biotech | Meals · 2025-02-20 | Tremfya | $119 |
See earlier years (2024, 2022)
2024: $44
| Abbvie | Rinvoq | $44 | 1 payment
|
2022: $125
| Abbvie | Skyrizi | $125 | 1 payment
|
Professional record
- NPI
- 1689775686
- Licence
- CA A50154California A50154: Current · expires 2027-05-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2006-09-25
- NPI last updated
- 2023-03-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1501 Trousdale Dr, Burlingame, CA, 94010